Abstract
Pneumocystis jirovecii pneumonia (PJP) is a potentially life-threatening infection that occurs in immunocompromised patients. PJP occurs in approximately 5–15% of transplant patients, depending on the transplanted organ and the degree of immunosuppression. In the absence of appropriate treatment, the mortality rate of PJP is 90–100%, and can be as high as 50% despite adequate therapy. Trimethoprim-Sulphamethoxazole (TMP-SMX) is the first choice for the treatment of PJP. Alternative drugs include intravenous Pentamidine, Dapsone, combination of Clindamycin and Primaquine (C+P).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
